ABERCROMBIE GEORGE B
Known title: DirectorCIK: 0001485939
Associated companies
Transaction History
| BCRX | ▲ Buy | Grant | 6,820 | $0 | 6/12/2024 | View on chart |
| BCRX | ▲ Buy | Grant | 16,745 | $0 | 6/13/2023 | View on chart |
| BCRX | ▲ Buy | Grant | 12,866 | $0 | 6/7/2022 | View on chart |
| BCRX | ▲ Buy | Option Exercise | 5,000 | $17K | 4/18/2022 | View on chart |
| BCRX | ▼ Sell | Open Market | 5,000 | $55K | 4/18/2022 | View on chart |
| BCRX | ▲ Buy | Option Exercise | 5,000 | $17K | 2/15/2022 | View on chart |
| BCRX | ▼ Sell | Open Market | 5,000 | $93K | 2/15/2022 | View on chart |
| BCRX | ▲ Buy | Option Exercise | 5,000 | $17K | 11/15/2021 | View on chart |
| BCRX | ▼ Sell | Open Market | 5,000 | $61K | 11/15/2021 | View on chart |
| BCRX | ▲ Buy | Option Exercise | 5,000 | $13K | 9/15/2021 | View on chart |
| BCRX | ▼ Sell | Open Market | 5,000 | $75K | 9/15/2021 | View on chart |
| BCRX | ▲ Buy | Option Exercise | 11,000 | $19K | 9/10/2021 | View on chart |
| BCRX | ▲ Buy | Option Exercise | 30,000 | $97K | 9/10/2021 | View on chart |
| BCRX | ▲ Buy | Option Exercise | 30,000 | $87K | 9/10/2021 | View on chart |
| BCRX | ▼ Sell | Open Market | 74,000 | $1.1M | 9/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BCRX Trades at 11x Forward Earnings, Analysts See $20.73 Target
BCRX is currently trading at about 11 times its forward earnings, which is on the lower side for the biotech sector. Analysts have an average target of $20.73, with a range from $11 to $32, while the stock sits near the bottom of its 52‑week range. This valuation gap raises questions about whether the market is pricing in potential challenges for the company.
BCRX Trades at 11x Forward Earnings, Analysts See $20.73 Target. BCRX is currently trading at about 11 times its forward earnings, which is on the lower side for the biotech sector. Analysts have an average target of $20.73, with a range from $11 to $32, while the stock sits near the bottom of its 52‑week range. This valuation gap raises questions about whether the market is pricing in potential challenges for the company.